Table 4.

Summary of findings table

Quality assessment							No of patients		Effect		Quality	Importance
No of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Interventionist care versus expectant care	Control	Relative (95% CI)	Absolute
Maternal: eclampsia—severe pre-eclampsia (≦34 weeks)
3	Randomised trials	No serious risk of bias	No serious inconsistencya	No serious indirectness	Seriousb	None	1/192 (0.52%)	1/197 (0.51%)	RR 1.02 (0.06 to 16.06)	0 More per 1000 (from 5 fewer to 76 more)	⊕⊕⊕O Moderate	Critical
								0%		−
Maternal: complications or progression to severe disease—pre-eclampsia or gestational hypertension (>34 weeks)
1	Randomised trials	Seriousc	No serious inconsistency	No serious indirectness	No serious imprecision	None	88/377 (23.3%)	138/379 (36.4%)	RR 0.64 (0.51 to 0.8)	131 Fewer per 1000 (from 73 fewer to 178 fewer)	⊕⊕⊕O Moderate	Critical
								36.4%		131 Fewer per 1000 (from 73 fewer to 178 fewer)
Maternal: placental abruption—severe pre-eclampsia (≦34 weeks)
4	Randomised trials	No serious risk of bias	No serious inconsistency	No serious indirectness	No serious imprecision	None	7/212 (3.3%)	16/215 (7.4%)	See comment	43 Fewer per 1000 (from 90 fewer to 0 more)	⊕⊕⊕⊕ High	Critical
								5.8%		34 Fewer per 1000 (from 70 fewer to 0 more)
Maternal: renal failure—severe pre-eclampsia (≦34 weeks)
4	Randomised trials	No serious risk of bias	No serious inconsistency	No serious indirectness	Seriousd	None	1/212 (0.47%)	4/215 (1.9%)	RR 0.33 (0.05 to 2.03)	12 Fewer per 1000 (from 18 fewer to 19 more)	⊕⊕⊕O Moderate	Critical
								1.1%		7 Fewer per 1000 (from 10 fewer to 11 more)
Maternal: HELLP Syndrome—severe pre-eclampsia (≦34 weeks)
3	Randomised trials	No serious risk of bias	No serious inconsistency	No serious indirectness	Seriouse	None	22/192 (11.5%)	20/197 (10.2%)	RR 1.12 (0.64 to 1.97)	12 More per 1000 (from 37 fewer to 98 more)	⊕⊕⊕O Moderate	Critical
								4.1%		5 More per 1000 (from 15 fewer to 40 more)
Maternal: HELLP Syndrome—pre-eclampsia or gestational hypertension (>34 weeks)
1	Randomised trials	Seriousf	No serious inconsistency	No serious indirectness	Seriousg	None	4/377 (1.1%)	11/379 (2.9%)	RR 0.37 (0.12 to 1.14)	18 Fewer per 1000 (from 26 fewer to 4 more)	⊕⊕OO Low	Critical
								2.9%		18 Fewer per 1000 (from 26 fewer to 4 more)
Maternal: disseminated coagulopathy—severe pre-eclampsia (≦34 weeks)
2	Randomised trials	No serious risk of bias	No serious inconsistency	No serious indirectness	Serioush	None	0/177 (0%)	2/182 (1.1%)	RR 0.2 (0.01 to 4.19)	9 Fewer per 1000 (from 11 fewer to 35 more)	⊕⊕⊕O Moderate	Important
								0.8%		6 Fewer per 1000 (from 8 fewer to 26 more)
Maternal: pulmonary oedema—severe pre-eclampsia (≦34 weeks)
2	Randomised trials	No serious risk of bias	No serious inconsistency	No serious indirectness	Seriousi	None	1/177 (0.56 %)	2/182 (1.1%)	RR 0.51 (0.05 to 5.53)	5 Fewer per 1000 (from 10 fewer to 50 more)	⊕⊕⊕O Moderate	Important
								0.8%		4 Fewer per 1000 (from 8 fewer to 36 more)
Maternal: postpartum hemorrhage (≥500 ml blood loss)—pre-eclampsia or gestational hypertension (>34 weeks)
1	Randomised trials	Seriousf	No serious inconsistency	No serious indirectness	No serious imprecision	None	35/377 (9.3%)	40/379 (10.6%)	RR 0.88 (0.57 to 1.35)	13 Fewer per 1000 (from 45 Fewer to 37 more)	⊕⊕⊕O Moderate	Critical
								10.6%		13 Fewer per 1000 (from 46 fewer to 37 more)

^aInconsistency: downgraded one level due to only one study providing data

^bImprecision: downgraded one level due to small sample size

^cRisk of bias: downgraded one level due to high risk of bias in blindness of patients, personnel and outcome assessor

^dImprecision: downgraded one level due to small sample size

^eImprecision: downgraded one level due to small sample size

^fRisk of bias: downgraded one level due to only one study providing data

^gImprecision: downgraded one level due to small sample size

^hImprecision: downgraded one level due to small sample size

ⁱImprecision: downgraded one level due to small sample size